Moving from ready-made drugs to bespoke biological blueprints
In short: Modern medicine often relies on average results from large populations, but your biology is unique. Personalised medicine seeks to replace this one-size-fits-all approach with bespoke treatments, using your specific genetic makeup and real-time data to predict illnesses, minimise side effects, and design therapies tailored specifically to your body.
Personalised medicine, often called precision medicine, shifts the focus from treating symptoms based on population averages to tailoring interventions to the individual. While common risk factors like age and cholesterol levels influence heart disease, our unique genetic makeup determines how significantly those factors actually impact our health. This variation means that two people with the same condition may experience different disease progressions and react differently to the same medications. By combining genetic, clinical, and lifestyle data, scientists aim to move beyond simple prescriptions toward predicting the likelihood of developing a condition before it manifests.
A key mechanism in this shift is the use of 'virtual' models. For instance, researchers at King’s College London are working to create digital versions of individual hearts using existing scanning techniques and electrical activity data. These models allow doctors to test different treatments in a virtual environment to predict success for complex conditions like heart failure or atrial fibrillation, where treatments for one condition might negatively affect the other. This allows for a level of precision that traditional 'ready-made' drugs cannot provide.
The logistical challenge of this bespoke approach is the fragility of biological materials. Some advanced therapies involve extracting a patient's own cells, gene-editing them, and re-injecting them. Because these cells have a very short shelf life outside the body, transporting them to a distant laboratory can be impossible. This has led to the emergence of 'point-of-care manufacture,' where medicines are produced directly within the hospital. Examples include treatments for multiple myeloma in Barcelona, severe burns in Switzerland, and research into red blood cell production in the UK. To make this viable, regulators are exploring models where manufacturers oversee production across multiple hospital sites to ensure consistent quality and safety.
Despite the promise, significant hurdles remain for the NHS and its suppliers. Implementing these bespoke devices and drugs requires navigating complex regulatory frameworks, ensuring high-quality production standards across different clinical settings, and managing the high-tech infrastructure needed to turn a patient's unique data into a life-saving treatment.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Personalised Medicine - Made For You - Martin Elliott
- Also: Personalised medicine: what is it, and how does it work?
- Also: Personalised medicine made in hospitals can revolutionise the way diseases are treated
To cite this card, link to https://intellectplus.co.uk/app/ideas-personalised-medicine-made-for-you-martin-elliott.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
